BiotechTube
Home/VERIGRAFT/Petter Björquist
PB

Petter Björquist

Chief Executive Officer

VERIGRAFT

Therapeutic Areas

Chronic Venous InsufficiencyPeripheral Artery DiseaseIschemic Heart DiseaseDialysis AccessPeripheral Nerve InjuryHeart Valve Disease

VERIGRAFT Pipeline

DrugIndicationPhase
P-TEVChronic Venous Insufficiency (CVI)Phase 2/3
P-TEAPeripheral Artery Disease (PAD)Preclinical
P-TENPeripheral Nerve DamagePreclinical
Personalized Heart ValveHeart Valve FailureResearch